Cover Image
市場調查報告書

克隆氏症:治療藥市場分析

Crohn's Disease: Full Disease Coverage

出版商 Datamonitor Healthcare 商品編碼 498956
出版日期 內容資訊 英文 315 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
克隆氏症:治療藥市場分析 Crohn's Disease: Full Disease Coverage
出版日期: 2017年12月17日 內容資訊: 英文 315 Pages
簡介

本報告提供克隆氏症治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:克隆氏症

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、手法
  • Cimzia (certolizumab pegol)
  • Cx601
  • Entyvio (vedolizumab)
  • etrolizumab
  • filgotinib
  • Humira (adalimumab)
  • mongersen (GED 0301)
  • Remicade (infliximab)
  • Stelara (ustekinumab)
  • Tysabri (natalizumab)
  • 一次調查手法

治療:克隆氏症

  • 摘要整理
  • 一次調查手法
  • 患者區分
  • 目前治療選擇
  • 處方趨勢
  • 遵守
  • 克隆氏症的未滿足需求
  • 處方的影響
  • 生物相似藥的影響

流行病學:克隆氏症

  • 摘要整理
  • 疾病的背景
  • 資訊來源、手法
  • 預測
  • 流行病學者的考察
  • 優勢、規定
  • 附錄

上市藥:克隆氏症

  • 摘要整理
  • 產品概要
  • 產品簡介:Cimzia
  • 產品簡介:Entyvio
  • 產品簡介:Humira
  • 產品簡介:Remicade
  • 產品簡介:Stelara
  • 產品簡介:Tysabri

開發平台:克隆氏症

  • 摘要整理
  • 臨床開發平台概要
  • 比較療法
  • 產品簡介 (後期) :Cx601
  • 產品簡介 (後期) :etrolizumab
  • 產品簡介 (後期) :filgotinib
  • 產品簡介 (後期) :mongersen

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5415

Disease Overview

Crohn's disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn's disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn's disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Market Snapshot

  • Stelara is set to become the leading brand in Crohn's disease as the longstanding anti-TNFs face biosimilar competition.
  • Infliximab - Remicade and its biosimilar versions - remains the most frequently prescribed biologic by surveyed physicians.
  • Crohn's disease is an expanding global health problem, with prevalent cases forecasted to increase in the majority of analyzed countries.
  • Gastroenterologists intend to prescribe Stelara over Entyvio due to its faster onset of action and comparable safety.
  • Mongersen's oral formulation and favorable safety will drive prescribing, despite its overall modest efficacy to date.

TABLE OF CONTENTS

FORECAST: CROHN'S DISEASE

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • Cimzia (certolizumab pegol)
  • Cx601
  • Entyvio (vedolizumab)
  • etrolizumab
  • filgotinib
  • Humira (adalimumab)
  • mongersen (GED 0301)
  • Remicade (infliximab)
  • Stelara (ustekinumab)
  • Tysabri (natalizumab)
  • Primary Research Methodology

TREATMENT: CROHN'S DISEASE

  • Executive Summary
  • Primary Research Methodology
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Compliance
  • Unmet Needs in Crohn's Disease
  • Prescribing Influences
  • Impact of Biosimilars

EPIDEMIOLOGY: CROHN'S DISEASE

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix

MARKETED DRUGS: CROHN'S DISEASE

  • Executive Summary
  • Product Overview
  • Product profile: Cimzia
  • Product profile: Entyvio
  • Product profile: Humira
  • Product profile: Remicade
  • Product profile: Stelara
  • Product profile: Tysabri

PIPELINE: CROHN'S DISEASE

  • Executive Summary
  • Clinical Pipeline Overview
  • Comparator Therapy
  • Product profile (late stage): Cx601
  • Product profile (late stage): etrolizumab
  • Product profile (late stage): filgotinib
  • Product profile (late stage): mongersen

LIST OF FIGURES

  • Figure 1: Crohn's disease sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Crohn's disease sales across the US, Japan, and five major EU markets, by class, 2016-25
  • Figure 3: Sales of Humira, Remicade, and their biosimilar versions in the US, Japan, and five major EU markets, 2016-25
  • Figure 4: Sales of Stelara, key branded anti-TNFs, and Entyvio in the US, Japan, and five major EU markets, 2016-25
  • Figure 5: Forecast sales of late-phase therapies in Crohn's disease across the US, Japan, and five major EU markets, 2016-25
  • Figure 6: Datamonitor Healthcare's Crohn's disease forecast methodology
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Cimzia sales in Crohn's disease across the US, Japan, and Spain, by country, 2016-25
  • Figure 9: Cx601 sales in Crohn's disease across the US and five major EU markets, by country, 2016-25
  • Figure 10: Entyvio sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Etrolizumab sales in Crohn's disease across the US and five major EU markets, by country, 2016-25
  • Figure 12: Filgotinib sales for Crohn's disease in the US and five major EU markets, 2016-25
  • Figure 13: Humira sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 14: Mongersen sales in Crohn's disease across the US and five major EU markets, by country, 2016-25
  • Figure 15: Remicade sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Stelara sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 17: Tysabri sales in Crohn's disease in the US, 2016-25
  • Figure 18: Severity of diagnosed Crohn's disease patients, by country
  • Figure 19: Mean percentage of Crohn's disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
  • Figure 20: Mean percentage use of systemic and non-systemic corticosteroids in the US, Japan, and five major EU markets, by line of therapy
  • Figure 21: Mean percentage of drug-treated Crohn's disease patients receiving monotherapy versus combination therapy, by line of therapy
  • Figure 22: Mean percentage of drug-treated Crohn's disease patients receiving anti-TNF therapy, by country and line of therapy
  • Figure 23: Mean percentage use of biologic therapies for the treatment of drug-treated Crohn's disease patients, by biologic and line of therapy
  • Figure 24: Mean compliance rates for drug-treated Crohn's disease patients, by formulation type
  • Figure 25: Top treatment challenges in Crohn's disease
  • Figure 26: Summary of future usage of biosimilar infliximab at one year and three years post-launch
  • Figure 27: Physician confidence in prescribing biosimilars for Crohn's disease approved on the basis of indication extrapolation, by country
  • Figure 28: Trends in diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 29: Absolute growth of diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 30: Male diagnosed prevalent Crohn's disease cases in each age group in the US, Japan, and five major EU markets, by country, 2015
  • Figure 31: Female diagnosed prevalent Crohn's disease cases in each age group in the US, Japan, and five major EU markets, by country, 2015
  • Figure 32: Datamonitor Healthcare's drug assessment summary for Crohn's disease
  • Figure 33: Cimzia for Crohn's disease - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Cimzia in Crohn's disease
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Cimzia in Crohn's disease
  • Figure 36: Entyvio for Crohn's disease - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Entyvio in Crohn's disease
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Entyvio in Crohn's disease
  • Figure 39: Humira for Crohn's disease - SWOT analysis
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Humira in Crohn's disease
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Humira in Crohn's disease
  • Figure 42: Remicade for Crohn's disease - SWOT analysis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Remicade in Crohn's disease
  • Figure 44: Datamonitor Healthcare's drug assessment summary of Remicade in Crohn's disease
  • Figure 45: Stelara for Crohn's disease - SWOT analysis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Stelara in Crohn's disease
  • Figure 47: Datamonitor Healthcare's drug assessment summary of Stelara in Crohn's disease
  • Figure 48: Tysabri for Crohn's disease - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Tysabri in Crohn's disease
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Tysabri in Crohn's disease
  • Figure 51: Cx601 for Crohn's disease - SWOT analysis
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Cx601 in Crohn's disease
  • Figure 53: Datamonitor Healthcare's drug assessment summary of Cx601 in Crohn's disease
  • Figure 54: Etrolizumab for Crohn's disease - SWOT analysis
  • Figure 55: Datamonitor Healthcare's drug assessment summary of etrolizumab in Crohn's disease
  • Figure 56: Datamonitor Healthcare's drug assessment summary of etrolizumab in Crohn's disease
  • Figure 57: Filgotinib for Crohn's disease - SWOT analysis
  • Figure 58: Datamonitor Healthcare's drug assessment summary of filgotinib in Crohn's disease
  • Figure 59: Datamonitor Healthcare's drug assessment summary of filgotinib in Crohn's disease
  • Figure 60: Mongersen for Crohn's disease - SWOT analysis
  • Figure 61: Datamonitor Healthcare's drug assessment summary of mongersen in Crohn's disease
  • Figure 62: Datamonitor Healthcare's drug assessment summary of mongersen in Crohn's disease

LIST OF TABLES

  • Table 1: Summary of key classes and brands and molecules included in Datamonitor Healthcare's Crohn's disease patientbased forecast
  • Table 2: Exchange rates used for calculating prices
  • Table 3: Datamonitor Healthcare's price assumptions for Cimzia
  • Table 4: Cimzia sales in Crohn's disease across the US, Japan, and Spain, by country ($m), 2016-25
  • Table 5: Cx601 sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • Table 6: Datamonitor Healthcare's price assumptions for Entyvio
  • Table 7: Entyvio sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 8: Etrolizumab sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • Table 9: Filgotinib sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • Table 10: Datamonitor Healthcare's price assumptions for Humira
  • Table 11: Humira sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 12: Mongersen sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • Table 13: Datamonitor Healthcare's price assumptions for Remicade
  • Table 14: Remicade sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 15: Datamonitor Healthcare's price assumptions for Stelara
  • Table 16: Stelara sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 17: Datamonitor Healthcare's price assumptions for Tysabri
  • Table 18: Tysabri sales in Crohn's disease in the US ($m), 2016-25
  • Table 19: Gastroenterologists surveyed for the Crohn's disease primary research study, 2016
  • Table 20: Gastroenterologists surveyed for the Crohn's disease primary research study, 2016
  • Table 21: Treatment guidelines: initial treatment of active Crohn's disease, by severity
  • Table 22: Treatment guidelines: maintenance of medically induced remission of Crohn's disease and other therapy recommendations
  • Table 23: Summary of key classes and products included in Datamonitor Healthcare's Crohn's disease survey
  • Table 24: Crohn's disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
  • Table 25: Mean percentage of drug-treated Crohn's disease patients receiving each drug class, by line of therapy and country (%)
  • Table 26: Mean percentage of drug-treated Crohn's disease patients receiving monotherapy or combination therapy, by line of therapy and country (%)
  • Table 27: Mean percentage of drug-treated Crohn's disease patients receiving each biologic therapy, by line of therapy and country (%)
  • Table 28: Compliance rates for Crohn's disease patients, by formulation type and country (%)
  • Table 29: Relative importance of treatment challenges in Crohn's disease, by country
  • Table 30: Relative importance of factors that influence gastroenterologists' prescription of biologics and aminosalicylates in Crohn's disease, by country
  • Table 31: Initial usage of biosimilar infliximab, according to respondents using biosimilar infliximab at the time of the survey, by country (%)
  • Table 32: Expected usage of biosimilar infliximab, according to respondents who did not prescribe biosimilar infliximab at the time of the survey, by country (%)
  • Table 33: Inflammatory bowel disease risk factors
  • Table 34: Montreal classification of Crohn's disease
  • Table 35: Sources used for Crohn's disease analysis in the US, Japan, and five major EU markets
  • Table 36: Notable sources not used for Crohn's disease analysis in the US, Japan, and five major EU markets
  • Table 37: Summary of Crohn's disease data processing in the US, Japan, and five major EU markets
  • Table 38: Diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 39: Age- and gender-specific diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015
  • Table 40: Phenotypic distribution of Crohn's disease at diagnosis, by Montreal classification and country, 2015
  • Table 41: Key marketed drugs for Crohn's disease
  • Table 42: Cimzia drug profile
  • Table 43: Cimzia pivotal trial data in Crohn's disease
  • Table 44: Cimzia late-phase trial data in Crohn's disease
  • Table 45: Entyvio drug profile
  • Table 46: Entyvio pivotal trial data in Crohn's disease
  • Table 47: Entyvio ongoing late-phase clinical trials in Crohn's disease
  • Table 48: Humira drug profile
  • Table 49: Humira pivotal trial data in adult Crohn's disease
  • Table 50: Humira pivotal trial data in pediatric Crohn's disease
  • Table 51: Humira ongoing trials in Crohn's disease
  • Table 52: Remicade drug profile
  • Table 53: Remicade pivotal trial data in adult Crohn's disease
  • Table 54: Remicade pivotal trial data in pediatric Crohn's disease
  • Table 55: Stelara drug profile
  • Table 56: Stelara pivotal trial data in Crohn's disease
  • Table 57: Tysabri drug profile
  • Table 58: Tysabri pivotal trial data in Crohn's disease
  • Table 59: Late-phase pipeline products in development for Crohn's disease
  • Table 60: Remicade drug profile
  • Table 61: Remicade pivotal trial data in adult Crohn's disease
  • Table 62: Remicade pivotal trial data in pediatric Crohn's disease
  • Table 63: Cx601 drug profile
  • Table 64: Cx601 Phase III trials in Crohn's disease
  • Table 65: Cx601 Phase I/II trials in Crohn's disease
  • Table 66: Etrolizumab drug profile
  • Table 67: Ongoing pivotal trials for etrolizumab in Crohn's disease
  • Table 68: Other late-phase trials for etrolizumab in Crohn's disease
  • Table 69: Filgotinib drug profile
  • Table 70: Ongoing pivotal Phase III trials of filgotinib in Crohn's disease
  • Table 71: Phase II trial data of filgotinib in Crohn's disease
  • Table 72: Mongersen drug profile
  • Table 73: Pivotal trials for mongersen in Crohn's disease
  • Table 74: Other ongoing Phase III trials for mongersen in Crohn's disease
  • Table 75: Phase II trial data for mongersen in Crohn's disease
Back to Top